Entera Bio (ENTX) grants COO 72,993 RSUs in lieu of cash bonus

Rhea-AI Filing Summary

Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that Chief Operating Officer Hillel Galitzer received a grant of 72,993 stock-settled restricted stock units at a stated price of $0.0000 per ordinary share. The Board approved the award on May 7, 2026 in lieu of a cash bonus he was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026. Following this equity award, Galitzer directly holds 163,566 ordinary shares of Entera Bio.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Galitzer Hillel

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares, par value NIS 0.0000769 per share	72,993	$0.00	--

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 163,566 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 72,993 units Shares after transaction: 163,566 shares Grant price per share: $0.0000 per share +1 more

4 metrics

RSUs granted 72,993 units Stock-settled restricted stock units granted May 7, 2026

Shares after transaction 163,566 shares Ordinary shares directly held by COO after grant

Grant price per share $0.0000 per share Stated price for granted ordinary shares

Vesting period 1 year, quarterly RSUs vest ratably on a quarterly basis over one year

Key Terms

stock-settled restricted stock units, in lieu of a cash bonus, vest ratably on a quarterly basis, Board of Directors

4 terms

stock-settled restricted stock units financial

"Represent a grant of stock-settled restricted stock units."

in lieu of a cash bonus financial

"This grant ... was awarded to the Reporting Person in lieu of a cash bonus"

vest ratably on a quarterly basis financial

"The restricted stock units vest ratably on a quarterly basis over a one-year period"

Board of Directors financial

"This grant ... was approved by the Board of Directors (the "Board") of Entera Bio Ltd."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galitzer Hillel

(Last) (First) (Middle)

KIRYAT HADASH,MINRAV BUILDING,5TH FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	05/07/2026		A		72,993	A	$0(1)	163,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Entera Bio (ENTX) COO Hillel Galitzer receive in this Form 4 filing?

Entera Bio’s COO Hillel Galitzer received 72,993 stock-settled restricted stock units. The award was approved by the Board on May 7, 2026 and granted as part of his compensation, increasing his direct holdings to 163,566 ordinary shares after the transaction.

Was the Entera Bio (ENTX) COO’s equity grant an open-market purchase or compensation?

The transaction is a compensation-related grant, not an open-market purchase. It is coded as a grant or award acquisition and consists of 72,993 restricted stock units provided in lieu of a cash bonus the executive was otherwise entitled to receive.

How do the Entera Bio (ENTX) COO’s new restricted stock units vest?

The 72,993 restricted stock units vest ratably on a quarterly basis over one year. The vesting period began on May 1, 2026, meaning portions of the award will settle into shares each quarter during that one-year schedule.

How many Entera Bio (ENTX) ordinary shares does the COO hold after this Form 4 transaction?

After the grant, the COO directly holds 163,566 ordinary shares. This total reflects his position following receipt of the 72,993 stock-settled restricted stock units that were awarded in lieu of a cash bonus under the company’s compensation arrangements.

Why did Entera Bio (ENTX) grant RSUs instead of paying a cash bonus to its COO?

The filing states that the 72,993 stock-settled restricted stock units were awarded in lieu of a cash bonus. This means the COO’s bonus entitlement was delivered as equity, aligning his compensation more closely with Entera Bio’s share performance.